AmyPore is working on an innovative therapeutic solution for patients and caregivers: the AmyP53 therapeutic peptide for the treatment of Alzheimer’s and Parkinson’s diseases. This would be a breakthrough in the prevention and treatment of these neurodegenerative diseases.
AmyPore is pleased to be collaborating with Aptar Pharma, a global leader in drug and consumer product dosing, dispensing and protection technologies, on the possible provision of an AmyP53 nasal spray allowing us to administer our solution non-invasively via the intranasal route.
Thanks to this strong partnership, AmyPore is moving towards a possible treatment of pathologies that need urgent solutions.
